{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:37:41Z","timestamp":1784266661049,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study investigated the long-term antihypertensive effects of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, alone or in combination with a calcium channel blocker (CCB) or a renin\u2013angiotensin system (RAS) inhibitor, in Japanese patients with essential hypertension. Patients were treated with esaxerenone starting at 2.5\u2009mg\/day increasing to 5\u2009mg\/day if required to achieve blood pressure (BP) targets as a monotherapy or with a CCB or RAS inhibitor. After the first 12 weeks of treatment, an additional antihypertensive agent could be added if required to achieve the target BP; the total treatment period was 28 or 52 weeks. The primary endpoint was a change from baseline in sitting BP. Of the 368 enrolled patients, 245 received monotherapy, and 59 and 64, respectively, took a CCB or RAS inhibitor concurrently. Mean changes from baseline in sitting systolic\/diastolic BP (95% confidence intervals) at weeks 12, 28 and 52 were \u221216.1 (\u221217.3, \u221214.9)\/\u22127.7 (\u22128.4, \u22126.9), \u221218.9 (\u221220.2, \u221217.7)\/\u22129.9 (\u221210.7, \u22129.2), and \u221223.1 (\u221225.0, \u221221.1)\/\u221212.5 (\u221213.6, \u221211.3) mmHg, respectively (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001 vs baseline). Similar BP reductions at these weeks were observed between all patient subgroups stratified by age, and the observed decreases in 24-h ambulatory BP were consistent with the efficacy observed in sitting BP. Esaxerenone was also well-tolerated with a rate of hyperkalemia at 5.4% (serum potassium \u22655.5\u2009mEq\/L), indicating a good safety profile for treatment over the long-term or in combination with a CCB or RAS inhibitor. In conclusion, esaxerenone may be a promising treatment option for patients with hypertension.<\/jats:p>","DOI":"10.1038\/s41440-019-0314-7","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T12:04:37Z","timestamp":1569413077000},"page":"1932-1941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension"],"prefix":"10.1038","volume":"42","author":[{"given":"Hiromi","family":"Rakugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"314_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/jhh.2008.27","volume":"22","author":"P Meneton","year":"2008","unstructured":"Meneton P, Galan P, Bertrais S, Heudes D, Hercberg S, Menard J. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. J Hum Hypertens. 2008;22:550\u20138.","journal-title":"J Hum Hypertens"},{"key":"314_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33\u201341.","journal-title":"N Engl J Med"},{"key":"314_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/01.HYP.37.3.845","volume":"37","author":"AH El-Gharbawy","year":"2001","unstructured":"El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845\u201350.","journal-title":"Hypertension"},{"key":"314_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/01.HYP.0000154364.00763.d5","volume":"45","author":"CE Grim","year":"2005","unstructured":"Grim CE, Cowley AW Jr., Hamet P, Gaudet D, Kaldunski ML, Kotchen JM, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension. 2005;45:766\u201372.","journal-title":"Hypertension"},{"key":"314_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1161\/HYPERTENSIONAHA.109.129320","volume":"53","author":"RM Reynolds","year":"2009","unstructured":"Reynolds RM, Walker BR, Phillips DI, Dennison EM, Fraser R, Mackenzie SM, et al. Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure. Hypertension. 2009;53:932\u20136.","journal-title":"Hypertension"},{"key":"314_CR6","doi-asserted-by":"publisher","first-page":"12a","DOI":"10.1016\/0002-9149(93)90239-9","volume":"71","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:A12\u20136.","journal-title":"Am J Cardiol"},{"key":"314_CR7","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","volume":"69","author":"CS Fox","year":"2006","unstructured":"Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D, et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int. 2006;69:2064\u20139.","journal-title":"Kidney Int"},{"key":"314_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","volume":"55","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55:1137\u201342.","journal-title":"Hypertension"},{"key":"314_CR9","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"314_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ajh.2008.225","volume":"21","author":"G Mule","year":"2008","unstructured":"Mule G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C, et al. Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens. 2008;21:1055\u201361.","journal-title":"Am J Hypertens"},{"key":"314_CR11","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","volume":"109","author":"MK Nishizaka","year":"2004","unstructured":"Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109:2857\u201361.","journal-title":"Circulation"},{"key":"314_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.107.100701","volume":"51","author":"E Pimenta","year":"2008","unstructured":"Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51:339\u201344.","journal-title":"Hypertension"},{"key":"314_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1378\/chest.06-1442","volume":"131","author":"MN Pratt-Ubunama","year":"2007","unstructured":"Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131:453\u20139.","journal-title":"Chest"},{"key":"314_CR14","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr., Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871\u20138.","journal-title":"Endocrinology"},{"key":"314_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925\u201330.","journal-title":"Am J Hypertens"},{"key":"314_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"314_CR17","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"314_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709\u201316.","journal-title":"Am J Hypertens"},{"key":"314_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839\u201345.","journal-title":"Hypertension"},{"key":"314_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"314_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"314_CR22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. J Am Med Assoc. 2015;314:884\u201394.","journal-title":"J Am Med Assoc"},{"key":"314_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jch.12860","volume":"18","author":"K Eguchi","year":"2016","unstructured":"Eguchi K, Kabutoya T, Hoshide S, Ishikawa S, Kario K. Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension. J Clin Hypertens (Greenwich). 2016;18:1250\u20137.","journal-title":"J Clin Hypertens"},{"key":"314_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129:661\u20136.","journal-title":"Am J Med"},{"key":"314_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jhh.2015.119","volume":"30","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. J Hum Hypertens. 2016;30:534\u201342.","journal-title":"J Hum Hypertens"},{"key":"314_CR26","unstructured":"Aldactone\u00ae (spironolactone) US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/012151s062lbl.pdf. Accessed 9 Oct 2018."},{"key":"314_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3\u201315.","journal-title":"J Hypertens"},{"key":"314_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/hr.2012.182","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res. 2013;36:185\u201390.","journal-title":"Hypertens Res"},{"key":"314_CR29","unstructured":"INSPRA\u00ae (eplerenone) US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21437lbl.pdf. Accessed 9 Oct 2018."},{"key":"314_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","volume":"177","author":"F Pelliccia","year":"2014","unstructured":"Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol. 2014;177:219\u201328.","journal-title":"Int J Cardiol"},{"key":"314_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"GC Roush","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens. 2016;34:11\u20139.","journal-title":"J Hypertens"},{"key":"314_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015;769:266\u201373.","journal-title":"Eur J Pharmacol"},{"key":"314_CR33","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharmacol. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"314_CR34","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2215\/CJN.14751218","volume":"14","author":"Sadayoshi Ito","year":"2019","unstructured":"Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria. a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;14:1161\u201372.","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"314_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542\u201351.","journal-title":"J Hum Hypertens"},{"key":"314_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/hr.2013.80","volume":"37","author":"K Shimamoto","year":"2014","unstructured":"Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253\u2013390.","journal-title":"Hypertens Res"},{"key":"314_CR37","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159\u2013219.","journal-title":"Eur Heart J"},{"key":"314_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41440-018-0201-7","volume":"42","author":"M Nishimoto","year":"2019","unstructured":"Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, et al. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019;42:514\u201321.","journal-title":"Hypertens Res"},{"key":"314_CR39","unstructured":"U.S. Food and Drug Administration, International Council for Harmonisation. E9 Statistical Principles for Clinical Trials. 2019. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073137.pdf. Accessed 4 Feb 2019."},{"key":"314_CR40","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/01.hjh.0000539672.65099.dd","volume":"36","author":"S Ito","year":"2018","unstructured":"Ito S, Ito H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. A double-blind phase III study of esaxerenone (CS-3150) compared to eplerenone in patients with essential hypertension (ESAX-HTN study). J Hypertens. 2018;36:e239.","journal-title":"J Hypertens"},{"key":"314_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","volume":"24","author":"P Kolkhof","year":"2015","unstructured":"Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015;24:417\u201324.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"314_CR42","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"314_CR43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"314_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","volume":"42","author":"A Nishiyama","year":"2019","unstructured":"Nishiyama A. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease. Hypertens Res. 2019;42:293\u2013300.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0314-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T17:03:48Z","timestamp":1650474228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0314-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1038\/s41440-019-0314-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YO and SY are employees of Daiichi Sankyo Co., Ltd. HR, SI, and HI declare that thay have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}